Showing results (271-280 of 283) with videos related to

Sort By:
Pageof 29
Journal of Gastroenterology|December 24, 2013
Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis CHatsue Fujino, Michio Imamura, Yuko Nagaoki, et al.
Oncology|February 12, 2018
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor ThrombosisKenichiro Kodama, Tomokazu Kawaoka, Hiroshi Aikata, et al.
Journal of Gastroenterology|May 6, 2017
Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapyKazuhiko Masuda, Atsushi Ono, Hiroshi Aikata, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 11, 2020
Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosisKazuki Ohya, Michio Imamura, Yuji Teraoka, et al.
Cancers|September 9, 2023
Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab TreatmentYosuke Tamura, Atsushi Ono, Hikaru Nakahara, et al.
Oncology|May 4, 2021
Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular CarcinomaYuwa Ando, Tomokazu Kawaoka, Kei Amioka, et al.
Oncology|September 4, 2020
Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with LenvatinibYuwa Ando, Tomokazu Kawaoka, Yosuke Suehiro, et al.
Cancers|October 27, 2022
Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular CarcinomaKei Amioka, Tomokazu Kawaoka, Takahiro Kinami, et al.
Oncology|May 17, 2021
Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular CarcinomaKensuke Naruto, Tomokazu Kawaoka, Kei Amioka, et al.
The New England Journal of Medicine|November 8, 2022
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B InfectionMan-Fung Yuen, Seng-Gee Lim, Robert Plesniak, et al.
Pageof 29